Kymab
ORI Capital exits investment in Kymab to Sanofi in a $1.1B deal, announces upcoming $400M ORI Fund II
Hong Kong-based healthcare fund management firm ORI Capital has decided to exit Kymab, a British biopharmaceutical company that specializes in vaccines and novel drug solutions.…
